Brief: Valbiotis Announces Success Of Reverse-It Phase Ii/Iii Clinical Study For Totum 63

Valbiotis SA

22/05/2023 17:01

May 22 (Reuters) - Valbiotis Sa  ALVAL.PA :
    * VALBIOTIS ANNOUNCES THE LARGE SUCCESS OF THE REVERSE-IT
INTERNATIONAL MULTICENTRIC PHASE II/III CLINICAL STUDY ON
TOTUM•63: PROVEN EFFICACY ON THE MAIN RISK FACTOR OF DEVELOPING
TYPE 2 DIABETES
    * THIS CLINICAL SUCCESS TRIGGERS A LUMP SUM PAYMENT OF CHF 4
MILLION FROM NESTLÉ HEALTH SCIENCE, AS PART OF GLOBAL STRATEGIC
PARTNERSHIP ON TOTUM•63
    * VALBIOTIS ANNOUNCES THE LARGE SUCCESS OF THE REVERSE-IT
INTERNATIONAL MULTICENTRIC PHASE II/III CLINICAL STUDY ON
TOTUM•63: PROVEN EFFICACY ON THE MAIN RISK FACTOR OF DEVELOPING
TYPE 2 DIABETES
    * STUDY ACHIEVED ITS OBJECTIVE ON PRIMARY ENDPOINT,
REDUCTION OF
FASTING BLOOD GLUCOSE, A RISK FACTOR FOR TYPE 2 DIABETES, AT A
5G DAILY DOSE IN 3 INTAKES PER DAY, WITH A HIGH STATISTICAL
SIGNIFICANCE
    * MILESTONE PAYMENT FROM NESTLÉ HEALTH SCIENCE WILL OCCUR
UPON
SUBMISSION OF FULL STUDY REPORT DURING SUMMER

Source text for Eikon:  ID:nBw3sjszja 
Further company coverage:  ALVAL.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))